During 1998–2010, AFMES recorded ≈18,500 deaths of active duty personnel for all causes. Of these, ≈14,000 were not attributed to combat or hostile action. Of the noncombat, non–hostile action deaths, 121 (0.9%) were caused by confirmed primary infections, including community acquired acute respiratory infections, meningitis, and chronic viral infections, such as hepatitis. Of these, 8 were attributed to adenovirus respiratory disease as the sole contributor or a co-contributor to death after review of available records by an AFMES pathologist (J.A.C.). For these 8 patients, the mean age was 21.3 years (range 18–32 years). Basic demographic data and adenovirus types are shown in the Table. In addition, most decedents were white (6 patients), 1 was black, and 1 was of unknown race. Brief clinical summaries of each case follow.

Patient A had a respiratory infection with adenovirus type 14, which was confirmed by testing of a nasal wash specimen. Several days later he was hospitalized and required care for multilobar pneumonia and acute respiratory distress syndrome. He died 8 days after admission. The autopsy showed necrotizing pneumonia with diffuse alveolar damage. Postmortem lung tissue was positive for adenovirus 14 by PCR.

Patient B was hospitalized with pneumonia 1 month after receiving a diagnosis of infectious mononucleosis. During a hospitalization of 83 days, her course of illness was complicated by multiple bacterial and fungal infections, acute respiratory distress syndrome, pneumothorax, bilateral deep vein thrombosis of lower extremities, acute renal failure, thrombocytopenia, seizures, acute disseminated encephalomyelitis, and acute hemorrhagic leukoencephalitis. PCR testing of serum on admission was positive for adenovirus. Postmortem lung findings included acute bronchopneumonia changes superimposed on diffuse alveolar damage with interstitial chronic inflammation and fibrosis. Postmortem lung tissue was positive for adenovirus 14 by PCR. This case was previously described as part of an adenovirus 14 outbreak (12).

Patient C was hospitalized with a 10-day history of treatment for presumed pyelonephritis, extreme weakness, fever, and nausea. He experienced severe sore throat, shortness of breath, chest pain, and mylagias early in the clinical course. Pericardial effusions and pericarditis were identified on the second hospital day. Results of antemortem microbiologic testing were negative, except for a positive serologic test for adenovirus on hospital day 1 with a serum titer of 128 (normal <8). Eighteen days after admission, he died from progressive respiratory failure. Postmortem findings included diffuse alveolar damage, pleural effusions, and fibrinous pericarditis. No postmortem microbiologic testing was done. The autopsy did not indicate a specific cause of death.

Patient D was treated for pneumonia as an outpatient. Two days later, he was found dead. Results of antemortem microbiologic testing were negative. Postmortem findings included pulmonary edema, congestion, and chronic inflammatory cell infiltrates with pleural effusions. Postmortem lung tissue was positive for adenovirus 4 by PCR.

Patient E was hospitalized and treated for pneumonia and died ≈25 days after admission. The autopsy showed pneumonia with superimposed fungal infection (consistent with aspergillosis) and septic emboli to the heart, brain, liver, spleen, gastrointestinal tract, and kidneys. Autopsy lung tissue was positive by PCR for adenovirus types 4 and 7.

Patient F became unresponsive during training and could not be resuscitated; his temperature was 105.5°F. He had sought treatment 1 week earlier for a presumed viral respiratory illness. The autopsy showed multilobar pneumonia. Lung tissue was PCR positive for adenovirus 4. Neisseria meningitidis was also identified by PCR and culture of lung tissue.

Patient G was found unresponsive on day 4 of outpatient treatment for a presumed upper respiratory infection. He was hospitalized and died 11 days later. Antemortem microbiologic testing results were negative. A complete autopsy was not performed, but selected specimens were obtained. A postmortem brain biopsy specimen showed histologic changes consistent with viral encephalitis. Brain and lung tissue were positive by PCR for adenovirus (13). Serum specimens had antibodies to adenovirus types 4 and 7 (13).

Patient H sought treatment as an outpatient for cough, shortness of breath, and fever of several days’ duration. The next day he returned with severe dyspnea, weakness, and a petechial rash. Patient H was noted to be in acute multiorgan failure and died within 12 hours. Antemortem testing was negative for microbiologic agents. The autopsy showed diffuse hemorrhagic pneumonia and diffuse alveolar damage. Results of postmortem viral and bacterial cultures were negative. By report, PCR of postmortem lung tissue was positive for adenovirus. This person also met the criteria for group A streptococcal toxic shock syndrome (13).

Of these 8 patients, only 3 had an adenovirus infection identified before death. The remaining 5 patients received a diagnosis on the basis of postmortem tissue examination. None had documentation of adenovirus vaccination.

Eight deaths among members of the US military were attributed to adenoviral respiratory disease by an AFMES pathologist during 1998–2010. All 8 deaths occurred after the adenovirus types 4 and 7 immunization program ended in 1999. Five earlier adenovirus-associated deaths in US military service members have been identified and documented. These occurred in 1967 (1 death), 1972 (3 deaths), and 1974 (1 death) (1,9,10). We did not identify any adenovirus-associated deaths in the US military during 1975–1998. Differences in medical surveillance and laboratory capabilities preclude attempting to make meaningful comparisons of the risk for adenovirus-associated death during the prevaccine, vaccine, and postvaccine periods.

The population at greatest risk for adenovirus-associated disease is military recruits. Therefore, the findings shown in the Table are not surprising. Most recruits are young men, and the deaths reported here occurred at the recruits’ training centers. Second-generation live oral vaccines against adenovirus types 4 and 7 were approved by the US Food and Drug Administration in March 2011 (14,15). After a 12-year absence, the adenovirus vaccination program for military recruits resumed in October 2011. Surveillance of the recruit centers will continue for evaluation of the types 4 and 7 vaccines. The military medical community is hopeful that the protective effect of the vaccines will extend beyond adenovirus types 4 and 7.